COl -you said you read all the reports-this is an extract from...

COl -you said you read all the reports-this is an extract from Stephen Jones on CBio site ASX releases dated 28/10/11-orphan drug status was discussed at AGM 29/11/2011----"CBio’s study, treatment of mice with XToll entirely prevented cutaneous lupus. XToll also significantly suppressed
nephritis in the kidneys, and significantly prolonged life span. In humans, nephritis in the kidneys is a major cause of
mortality and shortened life span of patients with lupus.
XToll also reduced the levels of pro-inflammatory cytokines such as IL-6 and TNF-alpha, a finding consistent with data
from the company’s phase IIa rheumatoid arthritis clinical trial.
This research indicates that in addition to rheumatoid arthritis, XToll could have utility in the treatment of human lupus,
either alone or as part of a drug combination therapy. It is estimated the lupus market will be worth $2.5 billion per annum
by 2017.
CBio Chairman Mr Stephen Jones said the publication of this data represents another milestone for the company and is
further corroboration of the strategy of the Board in its development program for XToll.
“The strategy of the Board has been to undertake projects that add the greatest value to XToll,” Mr Jones